Coya Therapeutics to Detail ALSTARS Trial Design at ALS Drug Development Summit
Event summary
- Coya Therapeutics will present the design of its ALSTARS Phase 2 trial at the 5th ALS Drug Development Summit on June 3, 2026.
- The trial focuses on COYA 302, a biologic combination therapy targeting neuroinflammation in ALS patients.
- COYA 302 combines low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig to enhance regulatory T-cell function.
- The ALSTARS trial is a randomized, multi-center, double-blind, placebo-controlled study.
The big picture
Coya Therapeutics' presentation at the ALS Drug Development Summit underscores the growing focus on neuroinflammation as a therapeutic target in neurodegenerative diseases. The company's approach of enhancing regulatory T-cell function with COYA 302 represents a novel strategy in ALS, a condition with limited treatment options. The success of the ALSTARS trial could validate this mechanism and position Coya as a key player in the neuroimmunology space.
What we're watching
- Trial Execution
- The pace at which Coya Therapeutics can enroll and complete the ALSTARS trial will determine the timeline for potential regulatory filings.
- Therapeutic Efficacy
- Whether COYA 302 can demonstrate meaningful efficacy in ALS patients, a field with high unmet medical need but also significant past failures.
- Competitive Positioning
- How Coya Therapeutics differentiates itself in the crowded ALS treatment landscape, particularly against other immunomodulatory approaches.
Related topics